Last reviewed · How we verify
AC-170 Vehicle
AC-170 Vehicle is a Small molecule drug developed by Nicox Ophthalmics, Inc.. It is currently in Phase 3 development for Ocular hypertension or glaucoma (Phase 3 development).
AC-170 Vehicle is a formulation component designed to deliver the active pharmaceutical ingredient AC-170 to ocular tissues.
AC-170 is a vehicle used in clinical trials for the treatment of allergic conditions such as Allergic Conjunctivitis, Atopic Disease, Rhinitis, and other allergic conditions. It has been tested in concentrations of 0.05%, 0.1%, and 0.24% in studies evaluating its efficacy in treating these conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AC-170 Vehicle |
|---|---|
| Sponsor | Nicox Ophthalmics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As a vehicle formulation, AC-170 Vehicle serves as the delivery system for the active drug AC-170, optimizing bioavailability and residence time in the eye. The specific mechanism of AC-170 itself is not publicly detailed, but the vehicle formulation is engineered to enhance ocular penetration and therapeutic efficacy for ophthalmologic conditions.
Approved indications
- Ocular hypertension or glaucoma (Phase 3 development)
Common side effects
Key clinical trials
- A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle (PHASE3)
- A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) (PHASE3)
- A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle (PHASE3)
- Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model (PHASE2)
- A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution (PHASE3)
- A Multi-Center Study Evaluating the Safety of AC-170 0.24% (PHASE3)
- Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AC-170 Vehicle CI brief — competitive landscape report
- AC-170 Vehicle updates RSS · CI watch RSS
- Nicox Ophthalmics, Inc. portfolio CI
Frequently asked questions about AC-170 Vehicle
What is AC-170 Vehicle?
How does AC-170 Vehicle work?
What is AC-170 Vehicle used for?
Who makes AC-170 Vehicle?
What development phase is AC-170 Vehicle in?
Related
- Manufacturer: Nicox Ophthalmics, Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Ocular hypertension or glaucoma (Phase 3 development)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing